Report Overview

Indian DPP-IV Inhibitor therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.

DPP IV inhibitors are a class of hypoglycaemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors, also called as gliptins, act as incretin enhancers. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body. DPP IV inhibitors are widely utilized as a treatment for type 2 diabetes.



Market Drivers

Increasein clinical trials on the DPP-4 drugs and increase in incidence of diabetes and its related complications such as cardiovascular disease, nephropathy, retinopathy, and neuropathy and rise in geriatric population fuel the market growth. However, the cost for DPP IV inhibitors is very high that might hinder the DPP IV Inhibitors Therapeutics Market.